The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Pfizer's revenues will shrink -12.9% and EPS will shrink -9.7%.
The average estimate for revenue is $13.12 billion. On the bottom line, the average EPS estimate is $0.56.
Last quarter, Pfizer logged revenue of $13.50 billion. GAAP reported sales were 9.3% lower than the prior-year quarter's $14.89 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.54. GAAP EPS of $0.38 for Q1 were 58% higher than the prior-year quarter's $0.24 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 80.7%, 140 basis points worse than the prior-year quarter. Operating margin was 33.1%, 120 basis points worse than the prior-year quarter. Net margin was 20.4%, 830 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $51.94 billion. The average EPS estimate is $2.17.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 5,491 members out of 6,080 rating the stock outperform, and 589 members rating it underperform. Among 1,549 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 1,452 give Pfizer a green thumbs-up, and 97 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pfizer is outperform, with an average price target of $29.99.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Pfizer. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Pfizer to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Dividend Stocks That Pay You More Than ExxonMobil Does
The oil giant pays its shareholders well, but there are opportunities out there for even higher payouts.
The 1 Word That Explains Why Pfizer's Future Looks Brighter Than Its Past
The big drugmaker had a clear message at the J.P. Morgan Healthcare Conference -- and it's a good one for investors.
3 Scorching-Hot Healthcare Stocks -- Are They Buys?
These three companies gained at least 400% in 2017. Can the good times continue?